within Pharmacolibrary.Drugs.ATC.A;

model A16AX08
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 2.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.103,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX08</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Teduglutide is a recombinant analog of human glucagon-like peptide-2 (GLP-2) used for the treatment of short bowel syndrome (SBS) in adult and pediatric patients who are dependent on parenteral nutrition. It enhances intestinal absorption by promoting mucosal growth, increasing intestinal blood flow, and reducing gastric motility. It is approved and in current use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following subcutaneous administration.</p><h4>References</h4><ol><li><p>Jeppesen, PB, et al., &amp; Joelsson, B (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. <i>Gastroenterology</i> 143(6) 1473–1481.e3. DOI:<a href=\"https://doi.org/10.1053/j.gastro.2012.09.007\">10.1053/j.gastro.2012.09.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22982184/\">https://pubmed.ncbi.nlm.nih.gov/22982184</a></p></li><li><p>Marier, JF, et al., &amp; Wallens, J (2010). Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn&#x27;s disease. <i>Journal of clinical pharmacology</i> 50(1) 36–49. DOI:<a href=\"https://doi.org/10.1177/0091270009342252\">10.1177/0091270009342252</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19773525/\">https://pubmed.ncbi.nlm.nih.gov/19773525</a></p></li><li><p>Marier, JF, et al., &amp; Caminis, J (2008). Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. <i>Journal of clinical pharmacology</i> 48(11) 1289–1299. DOI:<a href=\"https://doi.org/10.1177/0091270008320605\">10.1177/0091270008320605</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18974283/\">https://pubmed.ncbi.nlm.nih.gov/18974283</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX08;
